First-in-Human trial launches 'Living Drug' to hunt deadly cancer mutation
NCT ID NCT06043713
Summary
This is a first-in-human study testing a new, personalized cell therapy for people with advanced solid tumors that have spread and contain a specific genetic change called KRAS G12V. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to recognize and attack cancer cells with this mutation, and then infuse them back into the patient. The main goals are to find a safe dose and see if this approach can help control these difficult-to-treat cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.